Efficacy and Safety Study of Miconazole Oil Versus Vehicle on Fungal Infection of the Ear Canal (Otomycosis)

Randomized, Double-blind, Phase III Study of the Efficacy and Safety of Miconazole Oil Versus Vehicle Oil in the Treatment of Otomycosis, Followed by an Open-label Safety Evaluation

This study involves two portions, a randomized, double-blind portion and an open-label portion, to evaluate the efficacy and safety of Miconazole oil 2% versus its Vehicle in the treatment of fungal infection of the outer ear canal (Otomycosis). The subjects randomized in the first portion of the study will have active fungal infection of the ear(s) and will be treated with either Miconazole Oil or the Vehicle for 14 days twice daily, 5 drops into the affected ear(s) per dose. The subjects enrolled in the open-label portion of the study may or may not have active fungal infection of the ear(s), and will be given the Miconazole Oil active drug following the same application of 5 drops into the ear(s) twice daily for 14 days.

The intention of the study is to evaluate the efficacy of Miconazole Oil on fungal infection of the ears when applied using 5 drops into the ear(s) twice daily for 14 days continuously. This study also intends to show safety of Miconazole Oil 5 drops into each ear twice a day for 14 consecutive days.

Study Overview

• Status: Completed
• Conditions: Otomycosis
• Intervention / Treatment: Drug: miconazole 2% oil; Drug: vehicle oil

Detailed Description

This study will be conducted in 2 portions:

1. Enrollment A, which will consist of 2 treatment periods as follows and will be conducted in subjects with otomycosis:

   1. A randomized, double-blind, parallel-group treatment period. This treatment period will be referred to as the "Randomization Period" and will be followed by:
   2. An optional, open-label treatment period with miconazole oil. This treatment period will be referred to as the "Optional Open-label Extension."
2. Enrollment B will consist of open-label treatment with miconazole oil in subjects who will not be required to have signs and symptoms of otomycosis.

The study will start with Enrollment A, with an estimated 220 male or female subjects with otomycosis. Subjects will be randomly assigned in a 1:1 ratio to receive miconazole oil or vehicle (placebo), for 14 days. The study drug will be administered as 5 drops per ear at ~30 mg per drop instilled into the external ear canal of the ear(s) affected by otomycosis.

In the Randomization Period, both the subject and the investigator and study staff are blinded to the contents of the study drug.

At Screening/Baseline (Day 1), assessment of the signs and symptoms of otomycosis (pruritus, debris, visual examination for presence of fungal elements, and aural fullness), evaluation of medical history, pregnancy screening in female of childbearing potential, and, prior and concomitant medications, will be collected. Subjects with positive signs and symptoms of otomycosis and who meet all eligibility criteria will enter the study. Fungal culture of affected ear(s) will be taken, debris will be cleaned from the affected ear(s), and subject will be randomized and study drug dispensed. Treatment will be for 14 days. Day 8 On Treatment Visit will include clinical evaluation of otomycosis, cleaning of ear(s), and assessment of Adverse Events (AEs) and concomitant medications, and continue treatment up to Day 14. Day 15 End of Treatment Visit will include clinical evaluation of otomycosis and fungal culture, adverse events including Treatment emergent adverse events (TEAEs) and concomitant medications assessed. Day 22 Test of Cure Visit is an assessment of clinical signs and symptoms of otomycosis and fungal culture, AEs and concomitant medications assessed, and urine pregnancy test performed in women of childbearing potential.

Only the subjects that had positive fungal (mycological) culture at Baseline will be evaluated for efficacy. This is the Modified intent-to-treat (MITT) population.

The Optional Open-label Extension period will allow subjects to get miconazole oil for 14 days. No unblinding of the subject's treatment in the Randomization Period will occur at this time.

For Enrollment B, male or female subjects will be enrolled to receive miconazole oil to use for 14 days and will be evaluated for safety.

Intent-to-Treat (ITT) population are all subjects enrolled and randomized to treatment. Modified Intent-to-Treat (MITT) population are subjects in the ITT population with a clinical diagnosis of otomycosis confirmed by positive fungal culture at Baseline.

• Study Type: Interventional
• Enrollment (Actual): 382
• Phase: Phase 2; Phase 3

Contacts and Locations

Study Locations

• United States
  • California
    • Chula Vista, California, United States, 91910
      • Head and Neck Surgery Specialists
    • La Jolla, California, United States, 92037
      • UCSD
    • Roseville, California, United States, 95661
      • DaVinci Research, LLC
    • Sacramento, California, United States, 95815
      • Sacramento ENT / DaVinci Research
  • Florida
    • Leesburg, Florida, United States, 34748
      • Lake ENT & FPS
  • Kentucky
    • Louisville, Kentucky, United States, 40220
      • Advanced ENT & Allergy
  • Louisiana
    • New Orleans, Louisiana, United States, 70124
      • DelRicht Research
  • Missouri
    • Columbia, Missouri, United States, 65212
      • University of Missouri
  • South Carolina
    • Dillon, South Carolina, United States, 29536
      • Onsite Clinical Solutions
    • Orangeburg, South Carolina, United States, 29118
      • Carolina ENT
  • Texas
    • Houston, Texas, United States, 77055
      • West Houston Clinical Research Services
    • Plano, Texas, United States, 75093
      • Research Your Health

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 3 years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

Randomized blinded initial phase of study:

• Male or non-pregnant, non-lactating females with a clinical diagnosis of uncomplicated otomycosis of the external ear only,
• Intact tympanic membrane in the ear(s) to be treated with study drug,
• In general good health as determined by medical examination and medical history,
• Free of clinically significant disease, including diabetes mellitus, that is not well-controlled or that could interfere with the study.

Open-label second phase of study:

• Male or non-pregnant, non-lactating females with an intact tympanic membrane in the ear(s) to be treated with study drug,
• In general good health as determined by medical examination and medical history,
• Free of clinically significant disease, including diabetes mellitus, that is not well-controlled or that could interfere with the study.

Exclusion Criteria::

• Presence of dermatoses or conditions of the ear that may interfere with evaluation of otomycosis or with safety evaluations, including concomitant otic infections that require antimicrobial treatment,
• Disease that has spread beyond the external ear(s), or pre-existing skin atrophy of the affected ear(s);
• Tympanostomy tube or perforated tympanic membrane;
• History of prior surgery directly affecting and compromising the external auditory canal and/or tympanic membrane, except for prior tympanostomy tube(s) that have already been removed and completely healed;
• Use of any topical medicated treatments for otomycosis within 14 days of study entry;
• Use of any systemic antifungal therapy within 28 days of study entry, warfarin within 28 days of study entry, immunosuppressive or immune-stimulating drugs within 28 days of study entry, or systemic steroids within 3 months of study entry;
• Fever of ≥100°F at study entry;
• Otomycosis that has been unresponsive to previous antifungal treatment;
• Known hypersensitivity to any of the components in the test formulation;
• Participation in another investigative trial within 28 days of study entry

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Triple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Active treatment arm; Treatment with miconazole 2% oil, 5 drops into each ear twice daily for 14 consecutive days	Drug: miconazole 2% oil; Drug treatment of otomycosis for 14 days; Other Names: active treatment
Placebo Comparator: Placebo treatment arm; Treatment with the vehicle oil, placebo, 5 drops into each ear twice daily for 14 consecutive days	Drug: vehicle oil; Placebo treatment of otomycosis for 14 days; Other Names: placebo treatment
Other: Open-label treatment arm; Application of miconazole 2% oil, 5 drops into each ear twice daily for 14 consecutive days	Drug: miconazole 2% oil; Drug treatment of otomycosis for 14 days; Other Names: active treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Subjects With Therapeutic Cure	"therapeutic cure" is "mycological cure" plus "clinical cure, in the Modified intent to treat (MITT) only: patients with + fungal culture at baseline. Fungal culture results verified as (+) or (-) after enrollment. Intent to treat (ITT) population were all subjects enrolled and randomized. Active group: ITT=89 (100%), MITT=67 (75.3%); Placebo Group: ITT=90 (100%), MITT=64 (71.1%). Mycological cure is a negative mycological culture (culture is either positive or negative). Score=0 is best. Clinical cure is absence of all otomycosis signs and symptoms (s/s) of Pruritus, Debris, and Aural fullness, graded as (scores) 0=none, 1=mild, 2=moderate, 3=severe; and Presence of fungal elements, score 0=No fungal elements, 1=fungal elements present on visual inspection. Score=0 is best. Efficacy analysis was performed only on MITT (modified intent-to-treat) population, consisting of only those patients that had positive fungal culture at Baseline.	21 days from first day of drug application

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Subjects With Mycological Cure	Mycological cure is a negative mycological culture for the study ear at test of cure visit, in Modified intent to treat (MITT) only: patients with + fungal culture at baseline. Subjects that had negative fungal culture at Baseline were not included in MITT. Fungal culture results verified as (+) or (-) after enrollment. Grading is based on positive or negative mycological (fungal) culture. Negative culture is required. Efficacy analysis was performed only on MITT (modified intent-to-treat) population, consisting of only those patients that had positive fungal culture at Baseline. Intent to treat (ITT) population were all subjects enrolled and randomized. Active group: ITT=89 (100%), MITT=67 (75.3%); Placebo Group: ITT=90 (100%), MITT=64 (71.1%).	21 days from first day of drug application
Percentage of Subjects With Clinical Cure	Absence of all otomycosis signs and symptoms according to the scales for each individual sign/symptom. Score=0 is best. Clinical cure is absence of all otomycosis signs and symptoms of Pruritus, Debris, and Aural fullness, graded as (scores) 0=none, 1=mild, 2=moderate, 3=severe; and Presence of fungal elements, score 0=No fungal elements, 1=fungal elements present on visual inspection. Score=0 is best. Efficacy analysis was performed only on MITT (modified intent-to-treat) population, consisting of only those patients that had positive fungal culture at Baseline. Subjects that had negative fungal culture at Baseline were not included in MITT. Fungal culture results verified as (+) or (-) after enrollment. ITT (intent to treat) population were all subjects enrolled and randomized. Active group: ITT=89 (100%), MITT=67 (75.3%); Placebo Group: ITT=90 (100%), MITT=64 (71.1%).	21 days from first day of drug application

Collaborators and Investigators

• Sponsor: Hill Dermaceuticals, Inc.
• Collaborators: Abond CRO Inc.
• Investigators: Principal Investigator: Arnaldo Rivera, MD, University of Missouri-Columbia; Principal Investigator: Quyen T Nguyen, MD, UCSD; Principal Investigator: Kenneth Hodge, MD, Advanced ENT and Allergy; Principal Investigator: Patrick Dennis, MD, DelRicht Research; Principal Investigator: Sammy Vaught, MD, Lake ENT & FPS; Principal Investigator: Timothy Fitzgibbon, MD, Onsite Clinical Solutions; Principal Investigator: John Ansley, MD, Carolina ENT; Principal Investigator: Randall Ow, MD, DaVinci Research LLC; Principal Investigator: Oscar DeValle, MD, West Houston Clinical Research Service; Principal Investigator: Linda Woo, MD, Head and Neck Surgery Specialists; Principal Investigator: Brent Benscoter, MD, Sacramento ENT / DaVinci Research; Principal Investigator: Jeffrey Adelglass, MD, Research Your Health; Principal Investigator: Gary Brandt, MD, Delricht

Study record dates

Study Major Dates

• Study Start (Actual): July 8, 2020
• Primary Completion (Actual): November 1, 2021
• Study Completion (Actual): November 1, 2021

Study Registration Dates

• First Submitted: June 11, 2020
• First Submitted That Met QC Criteria: June 11, 2020
• First Posted (Actual): June 16, 2020

Study Record Updates

• Last Update Posted (Actual): January 19, 2024
• Last Update Submitted That Met QC Criteria: January 17, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Infections; Otorhinolaryngologic Diseases; Bacterial Infections and Mycoses; Ear Diseases; Mycoses; Otomycosis; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Enzyme Inhibitors; Hormones, Hormone Substitutes, and Hormone Antagonists; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Hormone Antagonists; Antifungal Agents; Steroid Synthesis Inhibitors; 14-alpha Demethylase Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors; Miconazole
• Other Study ID Numbers: MZ-0120-ESP3-052

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No